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The impact of point mutations in mitochondrial tRNA genes on the amount and stability of respiratory chain complexes and ATP synthase
(OXPHOS) has been broadly characterized in cultured skin fibroblasts, skeletal muscle samples, and mitochondrial cybrids. However, less is
known about how these mutations affect other tissues, especially the brain. We have compared OXPHOS protein deficiency patterns in skeletal
muscle mitochondria of patients with Leigh (8363GNA), MERRF (8344ANG), and MELAS (3243ANG) syndromes. Both mutations that affect
mt-tRNALys (8363GNA, 8344ANG) resulted in severe combined deficiency of complexes I and IV, compared to an isolated severe defect of
complex I in the 3243ANG sample (mt-tRNALeu(UUR)). Furthermore, we compared obtained patterns with those found in the heart, frontal cortex,
and liver of 8363GNA and 3243ANG patients. In the frontal cortex mitochondria of both patients, the patterns of OXPHOS deficiencies differed
substantially from those observed in other tissues, and this difference was particularly striking for ATP synthase. Surprisingly, in the frontal cortex
of the 3243ANG patient, whose ATP synthase level was below the detection limit, the assembly of complex IV, as inferred from 2D-PAGE
immunoblotting, appeared to be hindered by some factor other than the availability of mtDNA-encoded subunits.
© 2008 Elsevier B.V. All rights reserved.Keywords: Brain; COX — cytochrome c oxidase; Leigh syndrome; MELAS syndrome; MERRF syndrome; Tissue specificity1. Introduction
The mammalian organism fully depends on the oxidative
phosphorylation system (OXPHOS) as the major energy (ATP)
producer of the cell. Disturbances of OXPHOS may be caused
by mutations in either mitochondrial DNA (mtDNA) or
nuclear DNA, and environmental factors have also been
shown to have important effects on OXPHOS. In human
mitochondria, a small circular DNA molecule (16 659 bp)
codes for 13 polypeptides that form, together with nuclear-
encoded subunits, five inner-membrane OXPHOS complexes.Abbreviations: BN-PAGE, Blue-Native PAGE; COX, cytochrome c
oxidase, complex IV; CS, citrate synthase; mt-tRNA, mitochondrial tRNA;
mtDNA, mitochondrial DNA; OXPHOS, oxidative phosphorylation system;
SQR, succinate:coenzyme Q10 reductase, complex II
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doi:10.1016/j.bbadis.2008.02.001For the translation of these 11 mRNAs (nine monocistronic
and two bicistronic), mitochondria contain a separate transla-
tional system made of protein components, encoded exclu-
sively by nuclear genes and RNA components encoded by the
mitochondrial genome (two ribosomal RNA (rRNA) genes
and 22 transfer RNA (tRNA) genes). Mitochondrial translation
is precisely controlled to meet tissue-specific demands for
mtDNA-encoded structural subunits of the OXPHOS com-
plexes [1]. Although the basal components of the mito-
chondrial expression system are known, the mechanism of
regulation of the system in response to the metabolic needs of
the cell is poorly understood [2,3].
Since the late 1980s, large-scale deletions and point muta-
tions in mtDNA (approximately 120 in tRNAs and 11 in rRNAs)
have been identified to cause disorders of mitochondrial protein
synthesis, which is associated with defects of mitochondrial
bioenergetics in tissues that most depend on OXPHOS. Despite
numerous clinical studies on patients with mt-tRNA mutations,
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ization of OXPHOS insufficiency in skin fibroblast cultures or
skeletal muscle, little is known regarding tissue specificity of
OXPHOS deficiencies.
The aim of this study was to determine the steady-state levels
of OXPHOS protein complexes in the mitochondria of various
tissues (skeletal muscle, heart, frontal cortex and liver) of pa-
tients with mt-tRNA mutations. We chose (i) a patient with an
8363GNA mutation in mt-tRNALys, who died of Leigh syn-
drome; (ii) a patient with an 8344ANG mutation in the same
tRNA, who suffers from MERRF syndrome (myoclonic epi-
lepsy with ragged-red fibers); and (iii) a patient with a 3243ANG
mutation in mt-tRNALeu(UUR), who died of MELAS syndrome
(mitochondrial encephalomyopathy, lactic acidosis and stroke-
like episodes). In the skeletal muscle of these patients, the mu-
tations manifested themselves as described in previous studies
[4–11]; however, these results disclose new aspects of OXPHOS
deficiencies in the brain, particularly in the case of ATP syn-
thase. Furthermore, the 3243ANG frontal cortex mitochondria
showed a marked loss of the complex IV holoenzyme, accom-
panied by accumulation of assembly intermediates, which might
be caused by the virtual absence of complex V in this sample. A
similar phenomenon was described in yeast ATP synthase mu-
tants [12–15].
2. Patients, materials and methods
2.1. Ethics
This study was carried out in accordance with the Declaration of Helsinki of
the World Medical Association, and was approved by the Committee of Medical
Ethics of the Faculty of Medicine and General Faculty Hospital. Informed
parental consent, in accordance with the guidelines of the Faculty of Medicine,
Charles University, was obtained for all biopsies and autopsies.
2.2. Case reports
2.2.1. Patient 1, with an 8363GNA mtDNA mutation
The boy was born at term with a birth weight of 2590 g (5th percentile) and a
length of 48 cm. The early postnatal adaptation was uneventful, but a failure to
thrive and progressive hypotony developed beginning in infancy, and he was
wheelchair-dependent from the age of 8 years. Psychological investigations
revealed moderate mental retardation, which later became severe. At the age of
8 he had his first epileptic paroxysm, and at the age of 11, an acute stroke-like
encephalopathy developed, resulting in generalized weakness and respiratory
failure requiring ventilatory support. The liver function was unaffected and
aminotransferases were always within the reference range. The EEG pattern was
abnormal; an EMG demonstrated peripheral neuropathy, echocardiography
showed hypertrophic cardiomyopathy, and MRI revealed bilateral necrotic basal
ganglia lesions typical of Leigh syndrome. The boy died at the age of twelve.
Metabolic analyses revealed hyperlactacidemia (2.5–5.5 mmol/l, controls
b2.1 mmol/l) with an increased lactate/pyruvate ratio (L/P 28).
2.2.2. Patient 2, with a 3243ANG mtDNA mutation
The girl was born at term with a birth weight of 3140 g and a length of 50 cm.
Her early postnatal adaptation was uneventful, but a failure to thrive and growth
retardation were observed beginning in infancy. At the age of 16 years, her weight
and height were 30 kg and 140 cm (b3rd percentile). Cardiac evaluation revealed
dilated cardiomyopathy and Wolf–Parkinson–White syndrome. At the age of
18 years, blurred vision, emesis and tiredness developed, and subsequently,
seizures and coma. An MRI study showed symmetrical lesions within the basal
ganglia, compatible with Leigh syndrome, in addition to several hypodensities in
the subcortical regions of the frontal and occipital parts of the brain, which areconsistent with a diagnosis of acute ischemia. Metabolic analyses revealed
metabolic acidosis (BE-10 to -25 mmol/l, controls±2 mmol/l), as well as
increased levels of lactate in the blood (4–10 mmol/l, controls b2.1 mmol/l),
cerebrospinal fluid (12 mmol/l, controls b2.1 mmol/l), and urine (4976 mM/mol
creatinine, controls b60 mM/mol creatinine). Despite intensive treatment, the
girl died of progressive encephalomyopathy and respiratory failure due
to acquired infection during the terminal phase of the disease, at the age of
18 years.
2.2.3. Patient 3, with an 8344ANG mtDNA mutation
The boy was born at term with a birth weight of 3500 g and length of
51 cm, with normal postnatal adaptation. Beginning at the age of 11 years, he
developed progressive muscle weakness and paresthesia. Now, at the age of 15,
he has generalized muscle hypotrophy and hyporeflexia. No mental deteriora-
tion has been observed. An EMG disclosed diffuse myopathic abnormalities
and normal nerve conduction velocities. The EEG and cardiac evaluation were
normal. Metabolic analyses revealed an increased level of lactate in the blood
(5.6–7.88 mmol/l, controls b2.1 mmol/l) and lactate in the urine (5148 mM/mol
creatinine, controls b60 mM/mol creatinine).
2.3. Tissues
All studied tissues were obtained from three patients harbouring one of two
mutations in mt-tRNALys (8363GNA and 8344ANG) or one mutation in mt-
tRNALeu(UUR) (3243ANG), as well as from age-related controls. Open muscle
biopsies from the tibialis anterior muscle were frozen at -80 °C. Post-mortem
tissue specimens obtained at autopsy of 8363GNA and 3243ANG patients, and
controls were frozen less than 2 h after death. The studies were performed in
available stored material from the muscle (tibialis anterior), heart, liver, and
brain (frontal cortex).
2.4. mtDNA analysis
Total genomic DNA was isolated by phenol extraction from available tis-
sues. The DNA sample from the muscle biopsy of patient 1 was used for the
sequencing of the whole mtDNA molecule on an AbiPrism 3100 Avant Genetic
Analyser (Applied Biosystems).
To determine the amount of mtDNA containing the mutation, PCR/RFLP
analysis was performed. PCR products (8279–8485) were radioactively labelled
with [α-32P]dCTP in the final cycle of PCR, and run on a non-denaturing 10%
(w/v) polyacrylamide gel after complete digestion with TspRI (New England
BioLabs). The mutation abolishes one of two TspRI restriction sites on the
fragment. The proportions of wild-type to mutant mtDNAwere measured using
a PhosphorImager and ImageQuant software (Molecular Dynamics). The levels
of heteroplasmy of the 3243ANG and 8344ANG mutations were determined as
described elsewhere [16].
2.5. Electrophoresis
BN-PAGE (Blue-Native PAGE) [17] was used for the separation of mito-
chondrial membrane protein complexes on polyacrylamide 6–15% (w/v) gra-
dient gels using a MiniProtean® 3 System (Bio-Rad Laboratories). 5–50 μg of
protein, which was prepared as described previously [18], was loaded in each
lane. Two-dimensional BN/SDS/PAGE [17] was performed as described pre-
viously [18]. The protein content was measured by the Bio-Rad Protein Assay
(Bio-Rad Laboratories), using BSA as a standard.
2.6. Immunoblot analysis
Proteins were electroblotted from the gels onto Immobilon™-P PVDF
membranes (Millipore) using semi-dry transfer for 90min at a constant current of
0.8 mA/cm2. Membranes were air-dried overnight, rinsed twice with 100% (v/v)
methanol, and blocked in TBS and 10% (w/v) non-fat dried milk for 1–2 h.
Primary detection of BN/PAGE-blots was performed with mouse monoclonal
antibodies raised against the complex I subunit NDUFA9 (2 μg/ml), ATP syn-
thase subunit alpha (2-3 μg/ml), complex III subunit Core 2 (0.5 μg/ml), complex
IV subunit COX2 (0.5–1 μg/ml), and complex II subunit 70 kDa protein (1 μg/
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BN/SDS/PAGE-blots for the COX assembly was performed according to
Stiburek et al. [18]. Blots were incubated with primary antibodies in TBS, 0.3%
(v/v) Tween 20, and 2% non-fat dried milk for 2 h. Secondary detection was
carried out with a goat anti-mouse IgG-horseradish peroxidase conjugate
(1:1000–1:4000) (Sigma–Aldrich) in TBS, 0.1% Tween 20, and 2% non-fat
dried milk, for 1 h. The immunoblots were developed with SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce). The immunoblot-images of
chemiluminescence signals were captured using the VersaDoc Imaging System,
Model 4000 (Bio-Rad Laboratories), and analysed by the Quantity One
application (Bio-Rad Laboratories). All blotting experiments were repeated
with independently isolated mitochondrial samples. Duplicate experiments
yielded consistent results.
2.7. Spectrophotometric assays
The activities of respiratory chain complexes in isolatedmusclemitochondria
were measured spectrophotometrically by standard methods at 37 °C. NADH:
coenzyme Q10 reductase (NQR, complex I), succinate:coenzyme Q10 reductase
(SQR, complex II), succinate:cytochrome c reductase (SCCR, complex II+III),
NADH:cytochrome c reductase (NCCR, complex I+ III), coenzyme Q10:cyto-
chrome c reductase (QCCR, complex III), and cytochrome c oxidase (COX,
complex IV) were measured according to Rustin et al. [19], and citrate synthase
(CS) according to [20]. Total protein amount was determined by the method of
Lowry [21].
2.8. High resolution oxygraphy in muscle fibers
Muscle fibers were separated mechanically according to [22], and oxygen
consumption by saponin-skinned muscle fibers was determined using multiple
substrate inhibitor titrations as described previously [23].
3. Results
3.1. Heteroplasmy of mt-tRNA mutations in investigated tissues
Analyses of heteroplasmy by radioactive PCR-RFLP showed
80 – 97% heteroplasmy of mt-tRNA mutations in the tissues of
all patients (Table 1). Despite the narrow range of the mutation
load found in patient tissues, the severity of the clinical/func-
tional phenotype did not correlate with the level of heteroplasmy.Table 1
Summary of clinical consequences, mtDNA mutation loads and character of OXPH
Skeletal muscle 8363GNA
Clinical phenotype Myopathy (+++
Heteroplasmy 80%
OXPHOS protein deficiencies⁎ I and IV (↓↓↓),
ADP-stimulated respiration after pyruvate/glutamate/succinate ↓↓ /↓↓ /↑↑
Heart 8363GNA
Clinical phenotype Cardiomyopath
Heteroplasmy 89%
OXPHOS protein deficiencies I and IV and V
Frontal cortex 8363GNA
Clinical phenotype Encephalopathy
Heteroplasmy 87%
OXPHOS protein deficiencies V (↓↓↓), I and
Liver 8363GNA
Clinical phenotype –
Heteroplasmy 97%
OXPHOS protein deficiencies I (↓↓)
–, absent; ++, moderate; +++, severe; ↓↓↓, b30% of control; ↓↓, 30 – 50% of contro
control value; ↑↑↑, N200% of mean control value; N, normal; nd, not done; sub-assem
⁎ relative steady-state protein levels (Western blot) correlated with activities of resp3.2. Steady-state levels of OXPHOS complexes in 8363GNA,
8344ANG and 3243ANG skeletal muscle
To investigate the impact of mtDNAmutations on the system
of oxidative phosphorylation, immunoblots of mitochondrial
fractions resolved by BN-PAGE were prepared. Dilutions of
samples from control mitochondria were loaded on the same gels
in order to express the residual steady-state levels of OXPHOS
complexes in the patient tissues as a percentage of control
values.
In the 8363GNA skeletal muscle sample obtained at autopsy,
profoundly decreased levels of complex I (5% of control) and
IV (b10% of control) were detected. The sample also revealed a
diminished amount of complex V holoenzyme (35% of control),
along with accumulated sub-complexes, most likely V⁎ (F1-
ATPase with several c-subunits) and F1-ATPase (Fig. 1A). The
same sub-complexes were also detected in a bioptic muscle
sample from the 8363GNA patient using BN-PAGE with Coo-
massie staining, followed by the second denaturing electropho-
retic dimension with silver staining (Fig. 2).
A very similar pattern, although less severe, was found in the
8344ANG skeletal muscle sample. The amount of complex I was
reduced to approximately 25% of control, the level of complex
IV holoenzyme was b15% of control, and the holoenzyme level
of complex V was decreased to 60% of the control value. Im-
munodetection of complex V further showed sub-complexes
similar to those observed in the 8363GNA sample (Figs. 1A, 2A).
In 3243ANG skeletal muscle, relative levels of OXPHOS
holoenzymes were normal, except for a decrease in the content
of complex I to 30% of control and complex IV to 60% of
control (Fig. 1A).
3.3. Steady-state levels ofOXPHOS complexes in other 8363GNA
and 3243ANG tissues
Only the 8363GNA and 3243ANG samples of heart, frontal
cortex, and liver tissue were available for comparison of theOS deficiencies in investigated tissues of the patiens
3243ANG 8344ANG
) Myopathy (++) Myopathy (++)
90% 89%
V (↓↓), Vsub I (↓↓) I and IV (↓↓↓), V (↓), Vsub
nd ↓ /N/↑↑↑
3243ANG 8344ANG
yH(++) CardiomyopathyD(++) –
89% nd
(↓↓↓), Vsub I (↓↓↓) nd
3243ANG 8344ANG
(++) Encephalopathy (++) –
89% nd
IV (↓↓) V (↓↓↓), I and IV (↓↓↓), IVsub nd
3243ANG 8344ANG
– –
87% nd
N nd
l/mean control value; ↓, N50% of control/mean control value; ↑↑, 160% of mean
bly intermediates of indexed complex were present; D- dilated; H- hypertrophic.
iratory chain complexes (spectrophotometry), (Fig. 3).
Fig. 1. Analysis of the assembly ofOXPHOS complexes by immunoblotting ofBN-PAGE.BN-PAGE of laurylmaltoside-solubilisedmitochondria isolated from autoptic
(8363GNA, 3243ANG) and bioptic (8344ANG) muscle (A) and from autoptic (8363GNA, 3243ANG) heart (B), frontal cortex (C) and liver (D) was electroblotted onto
PVDFmembranes and probedwith monoclonal antibodies that detect the native forms of the OXPHOS complexes. Three aliquots of control mitochondria corresponding
to the indicated dilutions of control samples were loaded on the same gels. The migration of holoenzymes (I–V) and molecular mass standards (kDa) are indicated; the
actual position of sub-complex V⁎ and/or F1 of complex V (⁎) in skeletal muscle (A) and heart (B) is directly below complex III (around 370–470 kDa).
320 D. Fornuskova et al. / Biochimica et Biophysica Acta 1782 (2008) 317–325impact of mtDNA mutations on the system of oxidative phos-
phorylation in skeletal muscle and other tissues (Table 1).
The 8363GNA heart sample showed the same considerable
reduction in complexes I (5% of control) and IV (b10% of
control) content as skeletal muscle, but despite the greater re-
duction of complex V holoenzyme (15% of control), there was asignificantly lower accumulation of F1-ATPase. The 3243ANG
heart sample had a pronounced reduction of complex I (20% of
control), similar to skeletal muscle (Fig. 1B).
In the 8363GNA frontal cortex, the assembly of complexes I
and IV were less affected than in the above-mentioned tissues.
The amount of complex I was decreased to 40% of control, and
Fig. 2. Complex V (V) subassemblies V⁎ and F1-ATPase (F1), compatible with
those described previously for T8993G mitochondria, ρ0 cells, or where mito-
chondrial translation has been inhibited. Long exposure of complex V immuno-
detection with the monoclonal antibody against the ATP-alpha subunit from
Fig. 1A (A). Coomassie staining of BN-PAGE (above) and silver staining of
two-dimensional BN/SDS/PAGE (below) of the 8363GNA sample obtained
from skeletal muscle (bioptic sample) (B).
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control. Conversely, complex V (b20% of control) appeared to
be the most severely affected member of the OXPHOS system.
The decrease was more substantial than in skeletal muscle;
nevertheless, no detectable sub-complexes could be found. The
3243ANG frontal cortex sample showed a dramatic reduction of
complex V to below the detection limits of the method, and of
complex I to 10% of the control value. Probing of the immu-
noblots with an anti-COX2 antibody showed a reduction of
complex IV to 20% of control, as well as the presence of a highFig. 3. Relative steady-state protein levels and activities of respiratory chain
complexes normalized to complex II (II) or citrate synthase (CS) in isolated
muscle mitochondria. The ratios of specific activities are expressed as the
percentage of the mean of the control values (reference ranges are shown).
Fractions by the x-axis indicate which ratios are concerned; I— complex I, III—
complex III, IV— complex IV, (wb)— the ratio of holoenzyme levels obtained
from a Western blot, (act.) — the ratio of specific activities obtained using
spectrophotometry.
Fig. 4. Subunit composition of complex IV subassemblies in skeletal muscle
obtained from the 8363GNA patient (bioptic sample). Two-dimensional BN/
SDS/PAGE of lauryl maltoside-solubilised mitochondria isolated from the
skeletal muscle of a control or the 8363GNA patient, obtained at biopsy, were
electroblotted onto PVDF membranes and probed with monoclonal antibodies
specific for the subunits COX1, COX2, COX4 and COX5A. The positions of
the holoenzyme (S4) and subassemblies (S1–S3) are indicated, along with the
migration of the molecular mass standard (kDa).
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pected OXPHOS deficiency pattern observed in brain tissue,
particularly in the 3243ANG patient, the immunoblotting was
also performed on the frontal cortex sample from another
3243ANG patient. In the only available sample with a 65% level
of heteroplasmy, the immunoblotting analysis revealed normal
levels of OXPHOS complexes in comparison to control (data
not shown).
Despite the highest level of heteroplasmy (Table 1), the
8363GNA liver sample only showed an isolated deficiency of
complex I (40% of control) (Fig. 1D). Steady-state levels of
OXPHOS complexes in the 3243ANG liver mitochondria were
comparable to control (data not shown).
3.4. Activities of respiratory chain complexes in 8363GNA,
8344ANG and 3243ANG skeletal muscle
To characterize the impact of the 8363GNA, 8344ANG and
3243ANG mutations on the function of respiratory chain com-
plexes, the specific activities of the respective enzymes and
citrate synthase (CS, control enzyme) were measured spectro-
photometrically. The values expressed as relative ratios of the
activities of complexes I, III and IV normalized to complex II
(II, SQR) or CS were compared to the relative ratios of steady-
state protein levels normalized to complex II (Fig. 3). Consistent
with immunoblotting results, the spectrophotometry revealed
lower activity ratios for complex I (I/II and I/CS) in the isolated
muscle mitochondria of all three patients, and a severe deficiency
of complex IV in 8363GNA and 8344ANG isolated muscle mi-
tochondria. The COX/SQR (IV/II) and COX/CS (IV/CS) activity
ratios in the 3243ANG patient were just below the control range.
3.5. Oxygraphic analysis in 8363GNA and 8344ANG skeletal
muscle fibers
The functional consequences of the 8363GNA mutation in
comparison to the 8344ANG mutation were analysed by high-
resolution oxygraphy of the patients' skeletal muscle fibers per-
meabilized by a low concentration saponin treatment (Table 2).Table 2
Oxygen consumption by saponin-permeabilized skeletal muscle fibers with
8363GNA and 8344ANG mutations
8363GNA 8344ANG Controls (n=9)
Mitochondrial respiration (nmol O2 min
−1 per mg of wet weight)
Pyruvate/malate 6.9 14.7 16–26
Glutamate/malate 5.1 16.5 10–22
Succinate 21.4 30.0 9–18
Ascorbate/TMPD 66.0 57.0 43–83
Value normalized to respiration after succinate addition
Pyruvate/malate 0.32 0.49 0.96–1.85
Glutamate/malate 0.24 0.55 0.83–1.72
Ascorbate/TMPD 3.08 1.90 3.50–5.98
Polarographic measurements were performed as multiple substrate-inhibitor
titration in the presence of 1 mM ADP with subsequent additions of pyruvate
(10 mM)/malate (5 mM) or glutamate (10 mM)/malate (5 mM); succinate
(10 mM); ascorbate (2 mM)/TMPD (500 μM).In both samples, a decrease of ADP-stimulated oxygen con-
sumption compared to control fibers was observed using pyru-
vate as a substrate, and an increase was found after succinate
addition. A pronounced reduction in ADP-stimulated respira-
tion was found after pyruvate (33% of the mean control value)
as well as after glutamate (32% of the mean control value)
additions in 8363GNA muscle fibers. Indeed, ADP-stimulated
respiration after succinate treatment increased to 158% of
the mean control value. In 8344ANG muscle fibers, ADP-
stimulated respiration after pyruvate addition was 70% of the
mean control value, but after glutamate, it was within the
reference range. Similarly to 8363GNA muscle fibers, the ADP-
stimulated respiration after succinate addition increased to
222% of the mean control value in the 8344ANG sample. The
absolute oxygen consumption after ascorbate+TMPD treat-
ment was, in both samples, within control levels; however,
normalization of the data to the level of respiration after
succinate addition revealed decreased ratios after treatment with
all of the substrates (Table 2).
3.6. Mitochondrial content in skeletal muscles with mt-tRNALys
mutations
In isolated muscle mitochondria, Western blotting showed
an increased level of complex II holoenzyme, which is entirely
encoded by nuclear DNA, up to 150% and 160% of control
in 8363GNA and 8344ANG patient samples, respectively
(Fig. 1A). After normalization, this leads to artificially de-
creased amounts of complex III in the skeletal muscle mito-
chondria of both patients (Fig. 3, Complex III). Accordingly,
the II/CS activity ratio remained on the upper border of
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mitochondrial membrane content (altered mitochondrial
morphology).
In tissue homogenates, the specific activity of CS was in-
creased to 380% and 285% of the mean control value in the
8363GNA and 8344ANG patient samples, respectively. His-
tochemistry revealed increased amounts of SDH product in
8363GNA skeletal muscle and ragged-red fibers in 8344ANG
skeletal muscle.
Based on the above-mentioned observations and on the
increased ADP-stimulated oxygen consumption after succinate
treatment (antimycin A-sensitive) of patients' skeletal muscle
fibers (Section 3.5), a proliferation of mitochondria with altered
morphology could be expected as a result of cellular energetic
imbalance.
3.7. Immunoblots of two-dimensional native/denaturing gels
Immunoblotting of BN/SDS/PAGE (native in the first di-
mension and denaturing in the second dimension) with COX1,
COX2, COX4 and COX5A antibodies was used to analyze the
assembly of complex IV in 8363GNA skeletal muscle, and to
confirm the alignment of the high molecular weight band iden-
tified in the 3243ANG frontal cortex after immunoblotting of
BN/PAGE with COX2 antibody.
In 8363GNA skeletal muscle, the level of free S1 sub-com-
plex was found to be below the detection limit of the method
(Fig. 4). This probably reflects the limiting character of the
COX1 subunit in the holoenzyme assembly.
In 3243ANG frontal cortex, significantly increased levels of
all known complex IV assembly intermediates were observed,
including free apoCOX1 (S1 sub-complex), apoCOX2, and
apoCOX5A (Fig. 5). The high molecular weight band just belowFig. 5. Subunit composition of complex IV subassemblies in the frontal cortex
obtained at autopsy of the 3243ANG patient. Two-dimensional BN/SDS/PAGE
of lauryl maltoside-solubilised mitochondria isolated from the frontal cortex of a
control or the 3243ANG patient, obtained at autopsy, were electroblotted onto
PVDF membranes and probed with monoclonal antibodies specific for the
subunits COX1, COX2, COX4 and COX5A. The positions of holoenzyme (S4)
and subassemblies (S1–S3, apoCOX2) are indicated, along with the migration
of the molecular mass standard (kDa).the COX holoenzyme, which was detected with anti-COX2
antibody (Fig. 1C), very likely represents the S3 assembly
intermediate (Fig. 5). Long exposure of the same immunoblot
also revealed the band representing free apoCOX2 subunit (data
not shown). This finding further supports the assumption that
the final reduction in the content of COX holoenzyme in the
3243ANG frontal cortexmitochondria is not caused solely by the
limiting character of mtDNA-encoded subunits of COX (trans-
lational defect, Fig. 4).
4. Discussion
This paper has presented a detailed analysis disclosing the
tissue-specific impact of the 8363GNA mtDNA mutation on the
amount, stability, and function of the OXPHOS complexes in a
patient who died of Leigh syndrome. Furthermore, these data
were compared with that from two other mtDNA mutations; the
first one in the same tRNA (8344ANG) and the other one in mt-
tRNALeu(UUR) (3243ANG), both of which are at least twice as
common as the total number of other mtDNA point mutations
known to cause disorders affecting the central nervous system
[24,25]. Although just one patient with a comparable level of
heteroplasmy was available per studied mutation, the observed
data demonstrate intriguing tissue-specific patterns of OXPHOS
protein deficiencies, with the most unexpected findings in the
3243ANG frontal cortex.
In the skeletal muscle of patient 1, the lowest level of
heteroplasmy but the most severe OXPHOS defect suggests a
more profound impact of the 8363GNA mutation on the trans-
lational system than that of the 8344ANG mutation. Concerning
the 3243ANG mutation, the relatively proportional levels of
heteroplasmy in 8344ANG and 3243ANG skeletal muscles, the
more significant decrease in the content of complex I, the severe
decrease in the amount of complex IV, and the slightly lower
level of complex V in patient 2 all indicate a less pronounced
impact of the 3243ANGmutation onmitochondrial translation in
this tissue. However, the different nuclear backgrounds [26–30],
distributions of heteroplasmy levels in cells and mitochondria
[25,31,32], and environmental factors [33,34] which have been
shown to influence expression of mitochondrial respiratory in-
sufficiency, prevent the reduction of these results to any simple
quantitative trait.
The frequency of UUR (Leu) codons in mitochondrially-
translated subunits of OXPHOS implies decreased steady-state
levels of complex I subunits, namely ND6, ND3, ND2 and ND5
(14–9 UURs) in 3243ANG mitochondria. In 8363GNA and
8344ANG mitochondria, the distribution of AAR (Lys) codons
anticipates diminished levels of ND5, ND2, ND4 and COX1
(21–10 AARs). Moreover, all these subunits contain two X/Lys/
Lys/X motifs, or one X/Lys/Lys/X and one Lys/X/Lys motif
(http://www.mitomap.org), which are apparently strong stalling
points for the ribosome. The particular abundance and distri-
bution of codons in mitochondrially-translated subunits of res-
piratory chain complexes appears to be a plausible explanation
for the isolated defect of complex I in the patient with a mutation
in mt-tRNALeu(UUR), along with the combined deficiency of
complexes I and IV in patients with mutations in mt-tRNALys.
324 D. Fornuskova et al. / Biochimica et Biophysica Acta 1782 (2008) 317–325Furthermore, the complete absence of unassembled apoCOX1
(S1) in the skeletal muscle of the 8363GNA patient, as revealed
by BN/SDS/PAGE immunoblotting, conforms to the limiting
character of the COX1 subunit in holoenzyme assembly. On the
contrary, the OXPHOS deficiency patterns found in the frontal
cortex mitochondria of the 8363GNA and 3243ANG patients
could suggest, similarly to [18], a specific character for brain
OXPHOS. First, in both frontal cortex samples, the decrease in
the content of complex V was more profound than in that of
complexes I and IV. Second, despite such a pronounced defect of
complex V, no sub-complexes similar to those observed in
skeletal muscle and heart could be detected, even when the
immunoblot exposure was prolonged (data not shown). Unfor-
tunately, no 8344ANG frontal cortex specimen was available for
the analysis. However, a selectively decreased expression of
COX2 subunit was previously reported in frontal cortex and
cerebellum of a MERRF patient [35]. F1-ATPase, which was
observed in heart, was found along with a sub-complex denoted
V⁎ in skeletal muscle. The sub-complex V⁎ is likely composed
of F1-ATPase and several c-F0 subunits. These sub-complexes
were described previously in 8993TNG mitochondria [36,37],
ρ0 cells [37], and in cells with inhibited mitochondrial trans-
lation [38]. The observed steady-state levels of OXPHOS com-
plexes suggest that the brain ATP synthase is most sensitive to
disturbances of the mitochondrial translational system caused by
the studied mt-tRNAmutations. Such a tissue-specific impact of
mt-tRNA mutations with comparable tissue heteroplasmy is
likely to result from tissue-specific variations in the nature of
mitochondria. Indeed, it was shown that the brain, liver and
kidney OXPHOS system is mainly controlled at the phosphor-
ylation level by ATP synthase and a phosphate carrier, in contrast
to the muscle and heart, where it is essentially controlled at the
level of the respiratory chain [39]. On the other hand, instead
of diminished energy provisions, an insufficient discharge of
mitochondrial membrane potential leading to reactive oxygen
species (ROS) production was proposed as the underlying pa-
thogenic mechanism of ATP synthase deficiency [40]. Accord-
ingly, the complete lack of complex V from 3243ANG frontal
cortex may be, apart from the translational defect, responsible
for the unusual assembly pattern of COX in this sample. Indeed,
it was shown in yeast that (i) cells deficient in ATP synthase have
a severe reduction of COX holoenzyme [12–15] and (ii) no
decrease in COX synthesis is observed in uncoupled ATP syn-
thase mutants, where the maintenance of mitochondrial poten-
tial is severely compromised by a massive proton leak through
the F0 sector [41,42]. Although the COX1 subunit was shown to
be a key regulatory target for COX reduction in yeast cells [12],
some other mechanism is likely to be involved in the hindered
assembly of COX in the 3243ANG frontal cortex mitochon-
dria, since this sample had high accumulated levels of all
three mitochondrially encoded subunits, either free or partially
assembled.
Although it is necessary to analyze considerably more sam-
ples with high levels of heteroplasmy (such samples are difficult
to obtain), these data show new effects of mt-tRNA mutations
on the brain which differ substantially from those described for
skeletal muscle, heart, and liver tissues.Acknowledgements
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